Georgiana Toma: Addressing Iron Deficiency Without Anemia
Georgiana Toma, Hematology resident at the University Emergency Hospital of Bucharest, shared a post on LinkedIn:
“Iron Deficiency Without Anemia
How many of our patients struggle with chronic fatigue, ‘brain fog’, or exercise intolerance, only to be told their labs are ‘perfectly normal’ because their Hemoglobin is within range?
As clinicians, we are trained to treat Anemia.
But modern Hematology is sounding the alarm on a much more subtle predator: Iron Deficiency Without Anemia (IDWA).
The ‘Normal Hemoglobin’ Trap
A patient can have a Hemoglobin of 14 g/dL and still be cellularly ‘starving’ for iron.
Iron isn’t just for making red blood cells; it’s a critical cofactor for mitochondrial function, DNA synthesis, and neurotransmitter metabolism.
When we only look at the CBC, we miss the Sideropenia that is sabotaging our patients’ recovery and quality of life.
A Multidisciplinary challenge:
The evidence for treating IDWA (typically defined as Ferritin <30–50 ng/mL) is now robust across specialties:
- cardiology: the FAIR-HF and CONFIRM-HF trials revolutionized the field. Correcting iron deficiency in heart failure patients—regardless of anemia status—improves ejection fraction and reduces hospitalizations.
- neurology: iron is the ‘engine’ for dopamine synthesis. In Restless Legs Syndrome (RLS), clinical guidelines now suggest targeting Ferritin levels above 75 ng/mL, far beyond standard ‘normal’ lab ranges.
- gynecology: we often focus on stopping the flow (menorrhagia) but neglect the cognitive and physical toll of depleted iron stores that persist long after the bleeding is managed.
- sportsmedicine : sideropenia impairs muscular oxidative capacity and increases lactate production, even when oxygen-carrying capacity (Hb) is intact.
Should we stop asking ‘Is the patient anemic?’ and start asking ‘Are the patient’s iron stores optimized for their specific pathology?’
Standard lab ranges for Ferritin (often starting at 15 ng/mL) frequently fail to account for the functional needs of a failing heart or a developing brain.”
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026
-
Apr 16, 2026, 09:21Aurore Ughetto: The Hemocompatibility Burden of Micro-Axial Flow Pump Support
-
Apr 16, 2026, 09:09Naung Latt Htun: High Clinical Suspicion in Acquired Hemophilia A is Essential
-
Apr 16, 2026, 08:58Chittal Raulji: ASH-ISTH 2026 Guidelines for Anticoagulant Prophylaxis for Pediatric VTE Is Now Live in Blood Advances
-
Apr 16, 2026, 08:47Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
-
Apr 16, 2026, 08:19M Rafiqul Islam: Post-Thrombectomy Blood Pressure Management in Acute Ischemic Stroke
-
Apr 16, 2026, 06:58Rob Maloney: From Past to Progress in Hemophilia Care in the Dominican Republic
-
Apr 16, 2026, 06:51Michael Ertl: Patient-Reported Outcomes Reveal Differences in Perceived Stroke Recovery